Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Catheter Cardiovasc Interv ; 86(2): E38-48, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24905889

RESUMEN

OBJECTIVES: The potential for beneficial effects of adipose-derived stem cells (ASCs) on myocardial perfusion and left ventricular dysfunction in myocardial ischemia (MI) has not been tested following intravenous delivery. METHODS: Surviving pigs following induction of MI were randomly assigned to 1 of 3 different groups: the placebo group (n = 7), the single bolus group (SB) (n = 7, 15 × 10(7) ASCs), or the divided dose group (DD) (n = 7, 5 × 10(7) ASCs/day for three consecutive days). Myocardial perfusion defect area and coronary flow reserve (CFR) were compared during the 28-day follow-up. Also, serial changes in the absolute number of circulating CD4(+) T and CD8(+) T cells were measured. RESULTS: The increases in ejection fraction were significantly greater in both the SB and the DD groups compared to the placebo group (5.4 ± 0.9%, 3.7 ± 0.7%, and -0.4 ± 0.6%, respectively), and the decrease in the perfusion defect area was significantly greater in the SB group than the placebo group (-36.3 ± 1.8 and -11.5 ± 2.8). CFR increased to a greater degree in the SB and the DD groups than in the placebo group (0.9 ± 0.2, 0.8 ± 0.1, and 0.2 ± 0.2, respectively). The circulating number of CD8(+) T cells was significantly greater in the SB and DD groups than the placebo group at day 7 (3,687 ± 317/µL, 3,454 ± 787/µL, and 1,928 ± 457/µL, respectively). The numbers of small vessels were significantly greater in the SB and the DD groups than the placebo group in the peri-infarct area. CONCLUSIONS: Both intravenous SB and DD delivery of ASCs are effective modalities for the treatment of MI in swine. Intravenous delivery of ASCs, with its immunomodulatory and angiogenic effects, is an attractive noninvasive approach for myocardial rescue.


Asunto(s)
Tejido Adiposo/citología , Vasos Coronarios/fisiopatología , Microvasos/fisiopatología , Infarto del Miocardio/cirugía , Trasplante de Células Madre , Función Ventricular Izquierda , Adulto , Animales , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Células Cultivadas , Circulación Coronaria , Modelos Animales de Enfermedad , Femenino , Xenoinjertos , Humanos , Microcirculación , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/inmunología , Infarto del Miocardio/fisiopatología , Imagen de Perfusión Miocárdica , Neovascularización Fisiológica , Neurogénesis , Recuperación de la Función , Volumen Sistólico , Sus scrofa , Factores de Tiempo , Complejos Prematuros Ventriculares/fisiopatología , Complejos Prematuros Ventriculares/prevención & control , Adulto Joven
2.
Antivir Ther ; 16(8): 1335-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22155915

RESUMEN

BACKGROUND: The use of abacavir and didanosine in HAART has been associated with an increased risk of myocardial infarction in HIV-infected patients. The aim of this study was to address the development of endothelial dysfunction in cultivated coronary artery endothelial cells (HCAECs) in response to abacavir, didanosine and tenofovir. We examined the impact of these drugs on the expression levels of the proinflammatory, oxidative stress and apoptosis regulating genes in HCAECs. METHODS: We tested gene and protein expression changes in HCAECs in response to abacavir, didanosine and tenofovir using quantitative real-time reverse transciptase PCR, FACS and ELISA. The assessed genes/proteins included the proinflammatory molecules VCAM-1, ICAM-1, MCP-1, RANTES and IL-6. In addition, we assessed the gene expression of the intracellular reactive oxygen producing NADPH oxidase subunit gp91(PHOX) and the apoptosis regulating molecules Bcl-2 and BAD. RESULTS: Exposure of HCAECs to abacavir, didanosine and tenofovir resulted in no statistically significant changes in any of the tested genes/proteins at any time point or at any concentration. CONCLUSIONS: We found no evidence that abacavir, didanosine or tenofovir had direct in vitro effects on coronary endothelial cell gene transcription and protein expression of the selected mediators. If abacavir or didanosine increase cardiovascular risk, it is likely not through the direct endothelial activation pathways tested in these experiments. However, further studies are needed to completely exclude the toxicity of abacavir or didanosine on endothelial cells.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Moléculas de Adhesión Celular/metabolismo , Vasos Coronarios/efectos de los fármacos , Citocinas/metabolismo , Células Endoteliales/efectos de los fármacos , Expresión Génica , NADPH Oxidasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Adenina/administración & dosificación , Adenina/efectos adversos , Adenina/análogos & derivados , Adenina/uso terapéutico , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/uso terapéutico , Apoptosis/efectos de los fármacos , Apoptosis/genética , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/etiología , Moléculas de Adhesión Celular/genética , Vasos Coronarios/citología , Vasos Coronarios/metabolismo , Citocinas/genética , Didanosina/administración & dosificación , Didanosina/efectos adversos , Didanosina/uso terapéutico , Didesoxinucleósidos/administración & dosificación , Didesoxinucleósidos/efectos adversos , Didesoxinucleósidos/uso terapéutico , Células Endoteliales/citología , Células Endoteliales/metabolismo , Expresión Génica/efectos de los fármacos , Perfilación de la Expresión Génica , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/fisiología , Humanos , Inflamación/genética , Inflamación/metabolismo , NADPH Oxidasas/genética , Organofosfonatos/administración & dosificación , Organofosfonatos/efectos adversos , Organofosfonatos/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Cultivo Primario de Células , Proteínas Proto-Oncogénicas/genética , Tenofovir
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA